Performance Comparison of Microfluidic and Immunomagnetic Platforms for Pancreatic CTC Enrichment
November 15, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Sunlenca
Synonyms :
lenacapavir
Class :
Capsid Inhibitors
Brand Name :
Sunlenca
Synonyms :
lenacapavir
Class :
Capsid Inhibitors
Dosage forms & Strengths:Â
Adult:Â
Injectable solutionÂ
463.5mg/1.5mLÂ
TabletÂ
300 mgÂ
2Â recommended dosage regimens:
Dose option 1
Initiation:
Day 1: 927 mg Subcutaneous (SC) (2 x 1.5 mL) and 600 mg orally (2 x 300 mg)Â
Day 2: 600 mg orally (2 x 300 mg)Â
Maintenance:
Every six months (26 weeks), plus or minus two weeks: 927 mg Subcutaneous (SC) (2 x 1.5 mL)Â
Dose option 2
Initiation:
Day 1-2: 600 mg orally (2 x 300 mg) dailyÂ
Day 8: 300 mg orally (1 x 300 mg)Â
Day 15: 927 mg Subcutaneous (SC)
Maintenance:
Every six months (26 weeks), plus or minus two weeks: 927 mg Subcutaneous (SC)
Â
Â
Pediatric:Â
Injectable solutionÂ
463.5mg/1.5mLÂ
TabletÂ
300 mgÂ
Refer adult dosing
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
CYP3A4 Inhibitors: they may diminish the serum concentration of hormonal contraceptives
CYP3A4 Inhibitors: they may diminish the serum concentration of hormonal contraceptives
CYP3A4 Inhibitors: they may diminish the serum concentration of hormonal contraceptives
CYP3A4 Inhibitors: they may diminish the serum concentration of hormonal contraceptives
CYP3A Inhibitors: they may diminish the serum concentration of hormonal agents
CYP3A Inhibitors: they may diminish the serum concentration of hormonal agents
CYP3A Inhibitors: they may diminish the serum concentration of hormonal agents
CYP3A Inhibitors: they may diminish the serum concentration of hormonal agents
CYP3A Inhibitors: they may diminish the serum concentration of hormonal agents
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may decrease the therapeutic effects of antiherpetic antivirals
may decrease the therapeutic effects of antiherpetic antivirals
may enhance the serum concentration
may enhance the serum concentration
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration when combined with nifedipine
may increase the serum concentration of abemaciclib
may increase the level of serum concentration of adagrasib
may increase the level of serum concentration of adagrasib
may increase or decrease the activity of this enzyme when combined with sparsentan
May enhance the serum concentration when combined with levomilnacipran
may enhance the serum concentration when combined with upadacitinib
may decrease the therapeutic effect of each other when combined
may enhance the serum concentration when combined with tolvaptan
may increase the QTc prolonging effect of QT-prolonging Class III Antiarrhythmics
It may enhance serum concentration when combined with CYP3A4 Inhibitors (Moderate)
CYP3A4 Inhibitors (Moderate) may increase the serum concentration when combined with Zanubrutinib
may enhance the serum concentration when combined
may enhance the concentration of serum when combined with ubrogepant
may enhance the serum concentrations of the active metabolites
may diminish the serum concentration of Voxelotor
may enhance the serum concentration when combined
may enhance the concentration of serum when combined with istradefylline
lonafarnib: they may enhance the serum concentration of CYP3A4 Inhibitors
sirolimus: they may enhance the serum concentration of CYP3A4 Inhibitors
may enhance the concentration of serum when combined with alfentanil
may enhance the concentration of serum when combined with astemizole
may enhance the concentration of serum when combined with avanafil
may enhance the concentration of serum when combined with avapritinib
may enhance the concentration of serum when combined with brigatinib
may enhance the concentration of serum when combined with bromocriptine
budesonide inhaled/formoterol/glycopyrrolate inhaledÂ
may enhance the concentration of serum when combined with budesonide
may enhance the concentration of serum when combined with cilostazol
may enhance the concentration of serum when combined with cisapride
may enhance the concentration of serum when combined with cobimetinib
may enhance the concentration of serum when combined with colchicine
may enhance the concentration of serum when combined with dapoxetine
may enhance the concentration of serum when combined with daridorexant
may enhance the concentration of serums when combined with deflazacort
may enhance the concentration of serum when combined with eliglustat
may enhance the concentration of serum when combined with encorafenib
may enhance the concentration of serum when combined with entrectinib
may enhance the concentration of serum when combined with eplerenone
may enhance the concentration of serum when combined with fentanyl
may enhance the concentration of serum when combined with guanfacine
may enhance the concentration of serum when combined with ibrutinib
may enhance the concentration of serum when combined with elacestrant
budesonide: they may enhance the serum concentration of CYP3A4 Inhibitors
may enhance the serum concentration of Ergot Derivatives
may enhance the QTc-prolonging effect of each other when combined
ripretinib: they may diminish the serum concentration of CYP3A4 Inducers
alfentanil: they may enhance the serum concentration of CYP3A Inhibitors
avanafil: they may enhance the serum concentration of CYP3A Inhibitors
budesonide: they may enhance the serum concentration of CYP3A Inhibitors
bromocriptine: they may enhance the serum concentration of CYP3A Inhibitors
cilostazol: they may enhance the serum concentration of CYP3A Inhibitors
cisapride: they may enhance the serum concentration of CYP3A Inhibitors
colchicine: they may enhance the serum concentration of CYP3A Inhibitors
dapoxetine: they may enhance the serum concentration of CYP3A Inhibitors
daridorexant: they may enhance the serum concentration of CYP3A Inhibitors
eliglustat: they may enhance the serum concentration of CYP3A Inhibitors
encorafenib: they may enhance the serum concentration of CYP3A Inhibitors
eplerenone: they may enhance the serum concentration of CYP3A Inhibitors
fentanyl: they may enhance the serum concentration of CYP3A Inhibitors
ivacaftor: they may enhance the serum concentration of CYP3A Inhibitors
lumateperone: they may enhance the serum concentration of CYP3A Inhibitors
lurasidone: they may enhance the serum concentration of CYP3A4 Inhibitors
CYP3A4 Inhibitors: they may enhance the serum concentration of mavacamten
mitapivat: they may enhance the serum concentration of CYP3A Inhibitors
naloxegol: they may enhance the serum concentration of CYP3A Inhibitors
omaveloxolone: they may enhance the serum concentration of CYP3A Inhibitors
pemigatinib: they may enhance the serum concentration of CYP3A4 Inhibitors
omaveloxolone: they may enhance the serum concentration of CYP3A4 Inhibitors
pexidartinib: they may enhance the serum concentration of CYP3A4 Inhibitors
pexidartinib: they may enhance the serum concentration of CYP3A Inhibitors
rimegepant: they may enhance the serum concentration of CYP3A Inhibitors
selpercatinib: they may enhance the serum concentration of CYP3A4 Inhibitors
selumetinib: they may enhance the serum concentration of CYP3A4 Inhibitors
sonidegib: they may enhance the serum concentration of CYP3A4 Inhibitors
suvorexant: they may enhance the serum concentration of CYP3A Inhibitors
tazemetostat: they may enhance the serum concentration of CYP3A4 Inhibitors
tolvaptan: they may enhance the serum concentration of CYP3A Inhibitors
vardenafil: they may enhance the serum concentration of CYP3A4 Inhibitors
venetoclax: they may enhance the serum concentration of CYP3A4 Inhibitors
voclosporin: they may enhance the serum concentration of CYP3A4 Inhibitors
zanubrutinib: they may enhance the serum concentration of CYP3A Inhibitors
may enhance the risk of side effects when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
sodium picosulfate, citric acid, and magnesium oxide
may diminish the effect of each other when combined
aclidinium: they may enhance the serum concentration of CYP3A Inhibitors
cimetropium: they may enhance the serum concentration of CYP3A4 Inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
inhibitors of the cytochrome P450 enzyme system, like ketoconazole and clarithromycin, have the potential to enhance the exposure and toxicity of rimonabant since it undergoes liver metabolism mediated by this enzyme system
may decrease the serum concentration of lenacapavir
may decrease the serum concentration of lenacapavir
may decrease the serum concentration of lenacapavir
may decrease the serum concentration of lenacapavir
may decrease the serum concentration of lenacapavir
may increase the levels of serum concentration of ergot derivatives
may increase the levels of serum concentration of ergot derivatives
may increase the levels of serum concentration of ergot derivatives
may increase the levels of serum concentration of ergot derivatives
may increase the levels of serum concentration of ergot derivatives
may increase the levels of serum concentration of ergot derivatives
may increase the levels of serum concentration of ergot derivatives
may increase the levels of serum concentration of ergot derivatives
may increase the levels of serum concentration of ergot derivatives
may increase the levels of serum concentration of ergot derivatives
lenacapavir: they may diminish the serum concentration of CYP3A4 Inducers
lenacapavir: they may diminish the serum concentration of CYP3A4 Inducers
may enhance the concentration of serum when combined with ergot derivatives
may enhance the concentration of serum when combined with ergot derivatives
may enhance the concentration of serum when combined with ergot derivatives
may enhance the concentration of serum when combined with ergot derivatives
may enhance the concentration of serum when combined with ergot derivatives
may enhance the serum concentration when combined with hormonal contraceptives
may enhance the serum concentration when combined with hormonal contraceptives
may enhance the serum concentration when combined with hormonal contraceptives
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
may enhance the serum concentration of P-glycoprotein/ABCB 1 inhibitors
may enhance the serum concentration when combined with hormonal contraceptives
may enhance the serum concentration when combined with hormonal contraceptives
may enhance the serum concentration when combined with hormonal contraceptives
may enhance the serum concentration when combined with hormonal contraceptives
may enhance the serum concentration
it increases the concentration of CYP3A4 substrates in the serum
they decrease the concentration of active metabolites of infigratinib in the serum
CYP3A4 inhibitors increase the concentration of pimozide in the serum
may increase the serum concentration of acalabrutinib
CYP3A4 inhibitors increase the concentration of active metabolites of simvastatin in the serum
May enhance the serum concentration when combined with CYP3A4 Substrates
may enhance the serum concentration of simeprevir
may enhance the serum concentration
may enhance the serum concentration of fostemsavir
may enhance the serum concentrations of flibanserin
may enhance the serum concentration of tafamidis
may diminish the serum concentration when combined with nintedanib
CYP3A4 Inhibitors (Moderate) may increase the serum concentration when combined with Sertindole
CYP3A4 Inhibitors (Moderate) may decrease serum concentrations when combined with the active metabolite(s) when combined with Infigratinib
CYP3A4 Inhibitors (Moderate) may increase the serum concentration when combined with methysergide
CYP3A4 Inhibitors (Moderate) may increase the serum concentration when combined with Pacritinib
may enhance serum concentrations of the active metabolites
may enhance the serum concentration when combined
may enhance the concentration of serum when combined with pimozide
they decrease the concentration of lurbinectedin in the serum
The serum concentration of alfuzosin can be increased by strong CYP3A4 inhibitors
may enhance the serum concentration when combined
may diminish the concentration of serum when combined with CYP3A4 substrates
may decrease the therapeutic effect when combined
may enhance the concentration of serum when combined with ergot derivatives
may enhance the concentration of serum when combined with ergot derivatives
may enhance the concentration of serum when combined with aprepitant
may enhance the concentration of serum when combined with asunaprevir
may enhance the concentration of serum when combined with bosutinib
may enhance the concentration of serum when combined with budesonide
may enhance the concentration of serum when combined with isavuconazonium sulfate
may enhance the concentration of serum when combined with domperidone
may enhance the concentration of serum when combined with eletriptan
may enhance the concentration of serum when combined with fosaprepitant
may enhance the concentration of serum when combined with ivabradine
may increase the serum concentration of each other when combined
fexinidazole: they may enhance the serum concentration of CYP3A4 inhibitors
fusidic acid: they may enhance the serum concentration of CYP3A inhibitors
trabectedin: they may diminish the serum concentration of CYP3A Inhibitors
aprepitant: they may enhance the serum concentration of CYP3A Inhibitors
asunaprevir: they may enhance the serum concentration of CYP3A Inhibitors
bosutinib: they may enhance the serum concentration of CYP3A Inhibitors
domperidone: they may enhance the serum concentration of CYP3A Inhibitors
elacestrant: they may enhance the serum concentration of CYP3A Inhibitors
fosaprepitant: they may enhance the serum concentration of CYP3A Inhibitors
ivabradine: they may enhance the serum concentration of CYP3A Inhibitors
lemborexant: they may enhance the serum concentration of CYP3A Inhibitors
lomitapide: they may enhance the serum concentration of CYP3A Inhibitors
methysergide: they may enhance the serum concentration of CYP3A Inhibitors
nisoldipine: they may enhance the serum concentration of CYP3A4 Inhibitors
pacritinib: they may enhance the serum concentration of CYP3A Inhibitors
sertindole: they may enhance the serum concentration of CYP3A Inhibitors
simeprevir: they may enhance the serum concentration of CYP3A Inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
by altering intestinal/hepatic CYP 3A4 metabolism, the activity of lenacapavir can be reduced by butabarbital
benzthiazide: it may increase the risk of adverse effects with CYP3A inhibitors
betaine: it may increase the risk of adverse effects with CYP3A inhibitors
carboplatin: it may increase the risk of adverse effects with CYP3A inhibitors
carfilzomib: it may increase the risk of adverse effects with CYP3A inhibitors
dactinomycin: it may increase the risk of adverse effects with CYP3A inhibitors
dapagliflozin: it may increase the risk of adverse effects with CYP3A inhibitors
may increase the levels of serum concentration of estrogen derivatives
may increase the levels of serum concentration of estrogen derivatives
bazedoxifene/conjugated estrogens
may increase the levels of serum concentration of estrogen derivatives
may increase the levels of serum concentration of estrogen derivatives
may increase the levels of serum concentration of estrogen derivatives
may increase the levels of serum concentration of estrogen derivatives
may increase the levels of serum concentration of estrogen derivatives
bazedoxifene/conjugated estrogens
may increase the levels of serum concentration of estrogen derivatives
may increase the levels of serum concentration of estrogen derivatives
may increase the levels of serum concentration of estrogen derivatives
may increase the levels of serum concentration of hormonal contraceptives
may increase the levels of serum concentration of hormonal contraceptives
may increase the levels of serum concentration of hormonal contraceptives
may increase the levels of serum concentration of hormonal contraceptives
may increase the levels of serum concentration of hormonal contraceptives
may increase the levels of serum concentration of hormonal contraceptives
may increase the levels of serum concentration of hormonal contraceptives
may increase the levels of serum concentration of hormonal contraceptives
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
synthetic conjugated estrogens, a
may increase the serum concentration
synthetic conjugated estrogens, b
may increase the serum concentration
synthetic conjugated estrogens, a
may increase the serum concentration
synthetic conjugated estrogens, b
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
bazedoxifene/conjugated estrogens
may increase the serum concentration
synthetic conjugated estrogens, a
may increase the serum concentration
synthetic conjugated estrogens, b
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentrations
may increase the levels of serum concentrations
may increase the levels of serum concentrations
may increase the levels of serum concentrations
may increase the levels of serum concentrations
may increase the levels of serum concentrations
may increase the levels of serum concentrations
may increase the levels of serum concentrations
may increase the levels of serum concentrations
may increase the levels of serum concentrations
may increase the levels of serum concentrations
may increase the levels of serum concentrations
may increase the levels of serum concentrations
may increase the levels of serum concentrations
may increase the levels of serum concentrations
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
It may enhance the effect when combined with pemigatinib by affecting CYP3A4 metabolism
may increase the levels of serum concentration
may increase the levels of serum concentration
acetaminophen and phenyltoloxamine
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
acetaminophen and phenyltoloxamine
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
acetaminophen and phenyltoloxamine
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
acetaminophen and phenyltoloxamine
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
acetaminophen and phenyltoloxamine
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
acetaminophen and phenyltoloxamine
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may enhance the levels of serum concentration
may enhance the levels of serum concentration
may enhance the levels of serum concentration
may enhance the levels of serum concentration
may reduce the levels of serum concentration
may reduce the levels of serum concentration
may reduce the levels of serum concentration
may reduce the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
it increases the concentration of CYP3A4 substrates in the serum
it increases the concentration of CYP3A4 substrates in the serum
antiviral agents (HCV): they may increase the hypoglycemic effect of antidiabetic drugs
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
When lenacapavir is used together with adenine, this leads to a reduction in the lenacapavir’s metabolism
may increase the serum concentration of abemaciclib
may increase the serum concentration of zopiclone
may enhance the serum concentration of CYP3A4 inhibitor
may increase the toxic effect of opioid agonists
may increase the serum concentration
may enhance the serum concentration
may diminish serum concentrations when combined with doxercalciferol
may enhance the serum concentrations
may increase the level of serum concentration of itraconazole
may increase the level of serum concentration of itraconazole
CYP3A4 inhibitors increase the concentration of carbamazepine in the serum
CYP3A4 inhibitors increase the concentration of iloperidone in the serum
CYP3A4 inhibitors increase the concentration of finerenone in the serum
CYP3A4 inhibitors increase the concentration of tacrolimus in the serum
may increase the serum concentration of pimecrolimus
may increase the serum concentration
CYP3A4 inhibitors increase the concentration of rivaroxaban
may reduce the effect of zavegepant
may enhance the serum concentration of dexamethasone
may increase the hypoglycemic effect of Antidiabetic Agents
may increase the QTc prolonging effect of QTc prolonging agents
may increase the serum concentration of Lidocaine
may decrease the serum concentration of CYP3A4 Inducers
may increase the levels of serum concentration of pimavanserin
CYP3A4 Inhibitors (Moderate) may increase the serum concentration when combined with Vilazodone
It may enhance serum concentration when combined with CYP3A4 Inhibitors (Moderate)
It may enhance serum concentration when combined with CYP3A4 Inhibitors (Moderate)
It may increase serum concentration when combined with CYP3A4 Inhibitors (Moderate)
It may enhance the serum concentration when combined with CYP3A4 Inhibitors (Moderate)
It may increase the serum concentration when combined with CYP3A4 Inhibitors (Moderate)
It may enhance the serum concentration when combined with CYP3A4 Inhibitors (Moderate)
It may enhance the serum concentration when combined with CYP3A4 Inhibitors (Moderate)
It may enhance the serum concentration when combined with CYP3A4 Inhibitors (Moderate)
It may enhance the serum concentration when combined with CYP3A4 Inhibitors (Moderate)
It may enhance the serum concentration when combined with CYP3A4 Inhibitors (Moderate)
It may enhance the serum concentration when combined with CYP3A4 Inhibitors (Moderate)
It may enhance the serum concentration when combined with CYP3A4 Inhibitors (Moderate)
It may enhance the serum concentration when combined with CYP3A4 Inhibitors (Moderate)
may enhance the serum concentration when combined with ziprasidone
methylprednisolone hemisuccinateÂ
may increase the levels of serum concentration
may decrease the levels of serum concentration
It may enhance the serum concentration when combined with dexamethasone
may enhance the concentration of serum when combined with alprazolam
may enhance the concentration of serum when combined with carbamazepine
may enhance the concentration of serum when combined with cyclosporine
may enhance the concentration of serum when combined with dofetilide
may enhance the concentration of serum when combined with ixabepilone
may enhance the concentration of serum when combined with midazolam
may enhance the concentration of serum when combined with nimodipine
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
bazedoxifene/conjugated estrogens
may increase the levels of serum concentration
synthetic conjugated estrogens, a
may increase the levels of serum concentration
synthetic conjugated estrogens, b
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
bazedoxifene/conjugated estrogens
may increase the levels of serum concentration
synthetic conjugated estrogens, a
may increase the levels of serum concentration
synthetic conjugated estrogens, b
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
bazedoxifene/conjugated estrogens
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
buprenorphine,long-acting injectionÂ
may enhance the serum concentration of Buprenorphine
may enhance the concentration of serum when combined with sirolimus
It may enhance the serum concentration when combined with CYP3A4 Inhibitors
It may enhance the serum concentration when combined with CYP3A4 Inhibitors
Strong inhibitors of CYP3A4 have the potential to increase the serum concentration of alosetron
The serum concentration of amlodipine can be increased by strong inhibitors of CYP3A4
The use of strong CYP3A4 inhibitors may elevate the serum concentration of benidipine
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
may enhance the serum concentration when combined with dexamethasone
may increase the hypoglycemic effect of Antidiabetic Agents
may increase the Glucose-lowering effect of Antidiabetic Agents
may enhance the serum concentration of Vitamin D Analogs
alprazolam: they may enhance the serum concentration of CYP3A4 Inhibitors
flibanserin: they may enhance the serum concentration of CYP3A Inhibitors
dofetilide: they may enhance the serum concentration of CYP3A Inhibitors
finerenone: they may enhance the serum concentration of CYP3A Inhibitors
ixabepilone: they may enhance the serum concentration of CYP3A Inhibitors
midazolam: they may enhance the serum concentration of CYP3A Inhibitors
nimodipine: they may enhance the serum concentration of CYP3A Inhibitors
simvastatin: they may enhance serum concentrations of CYP3A Inhibitors
triazolam: they may enhance the serum concentration of CYP3A Inhibitors
fusidic acid and betamethasoneÂ
may enhance the serum concentration when combined
fusidic acid and betamethasoneÂ
may enhance the serum concentration when combined
may enhance the concentration of serum when combined with alitretinoin
may enhance the concentration of serum when combined with amiodarone
may enhance the concentration of serum when combined with aripiprazole
may enhance the concentration of serum when combined with aripiprazole lauroxil
may enhance the concentration of serum when combined with atogepant
may enhance the concentration of serum when combined with atorvastatin
may enhance the concentration of serum when combined with avacopan
may enhance the concentration of serum when combined with axitinib
may enhance the concentration of serums when combined with bedaquiline
benzhydrocodone/acetaminophenÂ
may enhance the concentration of serum when combined with benzhydrocodone
may enhance the concentration of serum when combined with bortezomib
may enhance the concentration of serum when combined with brexpiprazole
may enhance the concentration of serum when combined with buprenorphine
may enhance the serum concentration when combined
may enhance the serum concentration when combined
may diminish the serum concentration of each other when combined
may enhance the concentration of serum when combined with methylprednisolone
framycetin, dexamethasone, and gramicidinÂ
may enhance the serum concentration when combined
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
clofazimine: they may enhance the serum concentration of CYP3A inhibitors
mometasone (Nasal): they may enhance the serum concentration of CYP3A Inhibitors
alfuzosin: they may enhance the serum concentration of CYP3A Inhibitors
alitretinoin: they may enhance the serum concentration of CYP3A Inhibitors
amiodarone: they may enhance the serum concentration of CYP3A Inhibitors
amlodipine: they may enhance the serum concentration of CYP3A Inhibitors
atorvastatin: they may enhance the serum concentration of CYP3A Inhibitors
axitinib: they may enhance the serum concentration of CYP3A Inhibitors
barnidipine: they may enhance the serum concentration of CYP3A Inhibitors
bedaquiline: they may enhance serum concentrations of CYP3A Inhibitors
benidipine: they may enhance the serum concentration of CYP3A Inhibitors
buprenorphine: they may enhance the serum concentration of CYP3A Inhibitors
cabozantinib: they may enhance the serum concentration of CYP3A Inhibitors
clindamycin: they may enhance the serum concentration of CYP3A4 Inhibitors
clozapine: they may enhance the serum concentration of CYP3A4 Inhibitors
clozapine: they may enhance the serum concentration of CYP3A Inhibitors
copanlisib: they may enhance the serum concentration of CYP3A4 Inhibitors
conivaptan: they may enhance the serum concentration of CYP3A4 Inhibitors
crizotinib: they may enhance the serum concentration of CYP3A4 Inhibitors
crizotinib: they may enhance the serum concentration of CYP3A Inhibitors
darifenacin: they may enhance the serum concentration of CYP3A4 Inhibitors
isavuconazonium sulfate: they may diminish serum concentrations of CYP3A Inhibitors
darifenacin: they may enhance the serum concentration of CYP3A Inhibitors
ebastine: they may enhance the serum concentration of CYP3A Inhibitors
erythromycin: they may enhance the serum concentration of CYP3A4 inhibitors
eszopiclone: they may enhance the serum concentration of CYP3A inhibitors
fedratinib: they may enhance the serum concentration of CYP3A inhibitors
felodipine: they may enhance the serum concentration of CYP3A inhibitors
fluticasone furoate: they may enhance the serum concentration of CYP3A4 inhibitors
gilteritinib: they may enhance the serum concentration of CYP3A inhibitors
halofantrine: they may enhance the serum concentration of CYP3A4 inhibitors
isradipine: they may enhance the serum concentration of CYP3A4 inhibitors
lapatinib: they may enhance the serum concentration of CYP3A inhibitors
levamlodipine: they may enhance the serum concentration of CYP3A4 Inhibitors
macitentan: they may enhance the serum concentration of CYP3A Inhibitors
manidipine: they may enhance the serum concentration of CYP3A Inhibitors
naldemedine: they may enhance the serum concentration of CYP3A4 Inhibitors
nilotinib: they may enhance the serum concentration of CYP3A4 Inhibitors
oliceridine: they may enhance the serum concentration of CYP3A4 Inhibitors
palovarotene: they may enhance the serum concentration of CYP3A4 Inhibitors
panobinostat: they may enhance the serum concentration of CYP3A4 Inhibitors
piperaquine: they may enhance the serum concentration of CYP3A4 Inhibitors
pirtobrutinib: they may enhance the serum concentration of CYP3A4 Inhibitors
quetiapine: they may enhance the serum concentration of CYP3A4 Inhibitors
ribociclib: they may enhance the serum concentration of CYP3A4 Inhibitors
rifabutin: they may enhance the serum concentration of CYP3A4 Inhibitors
salmeterol: they may enhance the serum concentration of CYP3A Inhibitors
saxagliptin: they may enhance the serum concentration of CYP3A4 Inhibitors
silodosin: they may enhance the serum concentration of CYP3A4 Inhibitors
tadalafil: they may enhance the serum concentration of CYP3A4 Inhibitors
terfenadine: they may enhance the serum concentration of CYP3A4 Inhibitors
udenafil: they may enhance the serum concentration of CYP3A4 Inhibitors
ulipristal: they may enhance the serum concentration of CYP3A4 Inhibitors
valbenazine: they may enhance serum concentrations of CYP3A4 Inhibitors
vemurafenib: they may enhance the serum concentration of CYP3A4 Inhibitors
vorapaxar: they may enhance the serum concentration of CYP3A4 Inhibitors
finerenone: they may enhance the serum concentration of CYP3A4 Inhibitors
fosphenytoin: they may enhance the serum concentration of CYP3A4 Inhibitors
lidocaine: they may enhance the serum concentration of CYP3A4 Inhibitors
porfimer: they may enhance the serum concentration of CYP3A4 Inhibitors
phenytoin: they may enhance the serum concentration of CYP3A4 Inhibitors
aliskiren: they may enhance the serum concentration of CYP3A4 Inhibitors
voriconazole: they may enhance the serum concentration of CYP3A4 Inhibitors
tizanidine: they may enhance the serum concentration of CYP3A4 Inhibitors
may enhance the serum concentration of each other when combined
betamethasone + salicylic acidÂ
may enhance the serum concentration of each other when combined
eluxadoline: they may enhance the serum concentration of CYP3A4 Inhibitors
oxatomide: they may enhance the serum concentration of CYP3A4 Inhibitors
revefenacin: they may enhance the serum concentration of CYP3A4 Inhibitors
tiotropium: they may enhance the serum concentration of CYP3A4 Inhibitors
glucagon: they may enhance the serum concentration of CYP3A4 Inhibitors
itopride: they may enhance the serum concentration of CYP3A4 Inhibitors
mianserin: they may enhance the serum concentration of CYP3A4 Inhibitors
topiramate: they may enhance the serum concentration of CYP3A4 Inhibitors
may enhance the serum concentration of CYP3A4 inhibitor
may enhance the serum concentration of CYP3A4 inhibitor
may enhance the serum concentration of CYP3A4 inhibitor
may enhance the serum concentration of CYP3A4 inhibitor
may enhance the serum concentration of CYP3A4 inhibitor
relebactam: it may decrease the excretion of CYP3A inhibitors
cabotegravir: it may decrease the excretion of CYP3A inhibitors
capmatinib: it may decrease the excretion of CYP3A inhibitors
cefaclor: it may decrease the excretion of CYP3A inhibitors
cefalotin: it may decrease the excretion of CYP3A inhibitors
bumetanide: it may decrease the excretion of CYP3A inhibitors
diclofenac: it may decrease the excretion of CYP3A inhibitors
dolutegravir: it may decrease the excretion of CYP3A inhibitors
emtricitabine: it may decrease the excretion of CYP3A inhibitors
it may decrease the excretion of CYP3A inhibitors
ketoprofen: it may decrease the excretion of CYP3A inhibitors
ketamine: it may increase the risk of adverse effects with CYP3A4 inhibitors
decamethonium: it may increase the risk of adverse effects with CYP3A4 inhibitors
ketamine: it may increase the risk of adverse effects with CYP3A4 inhibitors
levobetaxolol: it may increase the risk of adverse effects with CYP3A4 inhibitors
mefloquine: it may increase the risk of adverse effects with CYP3A4 inhibitors
memantine: it may increase the risk of adverse effects with CYP3A4 inhibitors
fluprednisolone: it may increase the risk of adverse effects with CYP3A inhibitors
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
they increase the concentration of active metabolites of CYP3A4 inhibitors in the serum
they increase the concentration of active metabolites of CYP3A4 inhibitors in the serum
they increase the concentration of active metabolites of CYP3A4 inhibitors in the serum
they increase the concentration of active metabolites of CYP3A4 inhibitors in the serum
they increase the concentration of active metabolites of CYP3A4 inhibitors in the serum
they increase the concentration of glasdegib in the serum
they increase the concentration of active metabolites of CYP3A4 inhibitors in the serum
they increase the concentration of active metabolites of CYP3A4 inhibitors in the serum
they increase the concentration of active metabolites of CYP3A4 inhibitors in the serum
they increase the concentration of active metabolites of CYP3A4 inhibitors in the serum
they increase the concentration of active metabolites of CYP3A4 inhibitors in the serum
CYP3A4 inhibitors increase the concentration of ubrogepant in the serum
CYP3A4 inhibitors increase the concentration of sirolimus in the serum
CYP3A4 inducers increase the concentration of buspirone in the serum
almotriptan serum concentration may also be increased by CYP3A4 inhibitors (strong)
Virion assembly, nuclear integration, replication, and host cell penetration are all stages of the HIV-1 reproduction cycle when it co-opts several host components.Â
The viral capsid is released into the cytoplasm of the host cell after first fusing with the membrane.Â
Each of the about 250 hexamers and precisely 12 pentamers that make up the capsid is made up of monomeric capsid proteins (CA).Â
A surface for interaction with host cell machinery is provided by the N-terminal and C-terminal domains (NTD/CTD) of each CA monomer.Â
Nucleoporin 153 and cleavage and polyadenylation specificity factor subunit 6 (CPSF6) are two host proteins that directly attach to the capsid and have been demonstrated to be necessary for capsid nuclear entry.Â
Frequency defined:Â
>10%Â
For SunlencaÂ
Injection site reactions, Grade 1Â
Injection site reactions, Grade 2Â Â
Creatinine >1.8 x ULN or ≥1.5 x baselineÂ
For YeztugoÂ
Injection site reaction, painÂ
Injection site reaction, erythemaÂ
Injection site reaction, noduleÂ
Injection site reaction, indurationÂ
1-10%Â
For SunlencaÂ
GlycosuriaÂ
HyperglycemiaÂ
ProteinuriaÂ
Injection site reactionÂ
NauseaÂ
For YeztugoÂ
Injection site reactionÂ
HeadacheÂ
NauseaÂ
VomitingÂ
Injection site reactionÂ
Before starting Yeztugo, as well as with each following injection, people must be tested for HIV-1 infection using a test that has been approved by the FDA to diagnose acute or primary HIV-1 infection.Â
People with untreated HIV-1 infection were found to utilize drugs that cause drug-resistant HIV1 variations.Â
Start only after a negative infection status has been verified.Â
Lenacapavir for PrEP recipients who contract HIV-1 must switch to a full HIV-1 treatment program.Â
Contraindication / Caution:Â
Contraindication:Â
Caution:Â
Â
Â
Pregnancy consideration:Â Â
Insufficient data is available regarding the use of the drug in pregnant females.Â
Breastfeeding warnings:Â Â
No data is available regarding the excretion of the drug in breast milk.Â
Pregnancy category:Â
PharmacologyÂ
lenacapavir is an antiviral drug that is being developed for the treatment of HIV-1 infection. It belongs to a class of drugs known as capsid inhibitors, which target the viral capsid protein that is essential for the viral replication process.Â
lenacapavir works by binding to the viral capsid protein and disrupting its structure, which prevents the virus from entering host cells and replicating. This results in the inhibition of viral replication and the reduction of viral load in the body.Â
PharmacodynamicsÂ
lenacapavir is a viral capsid inhibitor that is used to treat HIV-1 infections. It works by binding to a specific site on the viral capsid protein and inhibiting the formation of the viral core, which is essential for viral replication. This binding also causes structural changes in the capsid protein that lead to the disruption of the virus’s ability to infect new cells.Â
lenacapavir is highly selective for HIV-1, with little to no activity against other viruses or host cells. It has a high barrier to resistance, as mutations that would allow the virus to escape the drug’s effects would likely be lethal to the virus.Â
Overall, the pharmacodynamics of lenacapavir involve binding to the viral capsid protein and inhibiting the formation of the viral core, leading to a disruption of the virus’s ability to infect new cells and a significant reduction in viral load in patients with HIV-1 infection.Â
PharmacokineticsÂ
Absorption:Â
The bioavailability of lenacapavir is 6-10% after oral administration and 100% after subcutaneous administration. Its peak plasma time is 4 hours after oral administration and 77-84 days after subcutaneous administration. After oral administration, the absorption of lenacapavir is not significantly affected by a low-fat or high-fat meal.Â
Distribution:Â
lenacapavir is highly protein-bound (greater than 98.5%) and has a blood-to-plasma ratio of 0.5-0.7. Its volume of distribution is 19,240 L after oral administration and 9,500-11,700 L after subcutaneous administration.Â
Metabolism:Â
lenacapavir is metabolized through minor metabolic pathways, including CYP3A and UGT1A1. However, these pathways do not play a significant role in the overall metabolism of the drug.Â
Elimination and excretion:Â
The majority of lenacapavir is eliminated unchanged in the feces (76%) after oral administration, with less than 1% being excreted in the urine. Â
The half-life of lenacapavir is 10-12 days after oral administration and 8-12 weeks after subcutaneous administration. The clearance of the drug is 55 L/hr after oral administration and 4.2 L/hr after subcutaneous administration.Â
Â
A vial access device must be used; injection kit components are single use only.Â
Before delivering the solution, visually check the vials and the prepared syringe for discoloration and particle debris.Â
Use SC injections as soon as the solution has been removed from the vials.
After attaching the needle to the syringe, prime it to 1.5 mL and remove any air bubbles.Â
Patient information leafletÂ
Generic Name: lenacapavirÂ
Pronounced: len-a-cap-a-virÂ
Why do we use lenacapavir?Â
Lenacapavir is recommended for the management of HIV-1 infections that are resistant to multiple drugs.Â
It is recommended as part of pre-exposure prophylaxis (PrEP) to lower the risk of HIV-1 acquisition in sexually exposed individuals.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
